Literature DB >> 27314067

Rational targeting of BRAF and PI3-Kinase signaling for melanoma therapy.

Marian M Deuker1, Martin McMahon1.   

Abstract

Although mitogen-activated protein kinase (MAPK) inhibitors elicit initial regression of BRAF-mutated melanoma, drug resistance is an inevitable and fatal event. We recently reported that in genetically engineered mouse models of BRAF-mutated melanoma, isoform-selective phosphatidylinositol 3-kinase inhibition cooperates with MAPK pathway inhibition to forestall the onset of MAPK pathway inhibitor resistance.

Entities:  

Keywords:  Mechanisms of oncogenesis and tumor progression; mechanisms of resistance to therapy; novel therapeutic agents; novel therapeutic targets

Year:  2015        PMID： 27314067      PMCID： PMC4909456          DOI： 10.1080/23723556.2015.1033095

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.

Authors:  Victoria Marsh Durban; Marian M Deuker; Marcus W Bosenberg; Wayne Phillips; Martin McMahon
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

2.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Authors:  Vikas K Goel; Alexander J F Lazar; Carla L Warneke; Mark S Redston; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2006-01       Impact factor: 8.551

Review 3.  The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin.

Authors:  David C Whiteman; William J Pavan; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2011-08-16       Impact factor: 4.693

4.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Authors:  Jessie Villanueva; Adina Vultur; John T Lee; Rajasekharan Somasundaram; Mizuho Fukunaga-Kalabis; Angela K Cipolla; Bradley Wubbenhorst; Xiaowei Xu; Phyllis A Gimotty; Damien Kee; Ademi E Santiago-Walker; Richard Letrero; Kurt D'Andrea; Anitha Pushparajan; James E Hayden; Kimberly Dahlman Brown; Sylvie Laquerre; Grant A McArthur; Jeffrey A Sosman; Katherine L Nathanson; Meenhard Herlyn
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

5.  Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer.

Authors:  Carlotta Costa; Hiromichi Ebi; Miriam Martini; Sean A Beausoleil; Anthony C Faber; Charles T Jakubik; Alan Huang; Youzhen Wang; Madhuri Nishtala; Ben Hall; Klarisa Rikova; Jean Zhao; Emilio Hirsch; Cyril H Benes; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2014-12-24       Impact factor: 31.743

6.  Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.

Authors:  Shidong Jia; Zhenning Liu; Sen Zhang; Pixu Liu; Lei Zhang; Sang Hyun Lee; Jing Zhang; Sabina Signoretti; Massimo Loda; Thomas M Roberts; Jean J Zhao
Journal:  Nature       Date:  2008-06-25       Impact factor: 49.962

7.  Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

Authors:  Paolo A Ascierto; David Minor; Antoni Ribas; Celeste Lebbe; Anne O'Hagan; Niki Arya; Mary Guckert; Dirk Schadendorf; Richard F Kefford; Jean-Jacques Grob; Omid Hamid; Ravi Amaravadi; Ester Simeone; Tabea Wilhelm; Kevin B Kim; Georgina V Long; Anne-Marie Martin; Jolly Mazumdar; Vicki L Goodman; Uwe Trefzer
Journal:  J Clin Oncol       Date:  2013-08-05       Impact factor: 44.544

8.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Authors:  Hubing Shi; Willy Hugo; Xiangju Kong; Aayoung Hong; Richard C Koya; Gatien Moriceau; Thinle Chodon; Rongqing Guo; Douglas B Johnson; Kimberly B Dahlman; Mark C Kelley; Richard F Kefford; Bartosz Chmielowski; John A Glaspy; Jeffrey A Sosman; Nicolas van Baren; Georgina V Long; Antoni Ribas; Roger S Lo
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

9.  PTEN-deficient cancers depend on PIK3CB.

Authors:  Susan Wee; Dmitri Wiederschain; Sauveur-Michel Maira; Alice Loo; Christine Miller; Rosalie deBeaumont; Frank Stegmeier; Yung-Mae Yao; Christoph Lengauer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-28       Impact factor: 11.205

10.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330
  10 in total
  3 in total

Review 1.  The role of PI3'-lipid signalling in melanoma initiation, progression and maintenance.

Authors:  Gennie L Parkman; Mona Foth; David A Kircher; Sheri L Holmen; Martin McMahon
Journal:  Exp Dermatol       Date:  2021-11-09       Impact factor: 3.960

2.  BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1.

Authors:  Johannes Grimm; Anita Hufnagel; Marion Wobser; Andreas Borst; Sebastian Haferkamp; Roland Houben; Svenja Meierjohann
Journal:  Oncogenesis       Date:  2018-09-20       Impact factor: 7.485

3.  Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds.

Authors:  Veronika Palušová; Tereza Renzová; Amandine Verlande; Tereza Vaclová; Michaela Medková; Linda Cetlová; Miroslava Sedláčková; Hana Hříbková; Iva Slaninová; Miriama Krutá; Vladimír Rotrekl; Hana Uhlířová; Aneta Křížová; Radim Chmelík; Pavel Veselý; Michaela Krafčíková; Lukáš Trantírek; Kay Oliver Schink; Stjepan Uldrijan
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.